# CARE1 Pragmatic Clinical Trial

> **NCT06364631** · PHASE3 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 1250 (estimated)

## Conditions studied

- Metastatic Kidney Cancer
- Metastatic Kidney Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Pembrolizumab
- **DRUG:** Cabozantinib
- **DRUG:** Axitinib
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06364631
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2032-05-05
- **Final completion:** 2032-05-05
- **Target enrollment:** 1250 (ESTIMATED)
- **Last updated:** 2025-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364631, "CARE1 Pragmatic Clinical Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06364631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*